Cymbalta fibromyalgia indication
Lilly may be able to offer an alternative fibromyalgia treatment to Pfizer's Lyrica (pregabalin) by June 2008 if its sNDA for Cymbalta (duloxetine) is approved within a standard 10-month review. The filing was announced by the company Aug. 21. Cymbalta is approved for treatment of major depressive disorder, management of diabetic peripheral neuropathic pain and treatment of generalized anxiety disorder in adults. Separately, Lilly released clinical trial data for the serotonin-norepinephrine reuptake inhibitor showing greater reductions in pain severity one week after starting treatment compared to placebo. The sNDA is based on data from 1,400 patients across five clinical trials, the firm said. Pfizer has estimated the fibromyalgia indication could add $1 billion in incremental sales for Lyrica (1"The Pink Sheet" July 2, 2007, p. 17)...
You may also be interested in...
Pfizer's first steps in marketing Lyrica's new indication for fibromyalgia - the first FDA approval for the condition - will be partnering with patient advocacy groups to raise awareness and conduct educational programs
Health technology assessment body NICE has now recommended that selective internal radiation therapy can be used on England’s National Health Service for treating advanced liver cancer.
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.